touchPANEL DISCUSSION

Eosinophilic inflammatory diseases of the respiratory system: New therapeutic options

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Airway Disease, Asthma, Respiratory Tract Disorders Watch Time: 39 mins

touchPANEL DISCUSSION Eosinophilic inflammatory diseases of the respiratory system: New therapeutic options

Watch a panel of experts discuss how to identify and manage patients with inflammatory respiratory diseases, with a focus on severe eosinophilic asthma.

Dr Harissios Vliagoftis

University of Alberta, Edmonton, Alberta, Canada

CHAIR

Panelists:
Prof. Ian Pavord, Prof. Alberto Papi
 
Video Chapters
Introduction

Chair, Dr Harissios Vliagoftis, introduces the expert panel and agenda for this discussion on new therapeutic options for treating eosinophilic inflammatory diseases of the respiratory system.

view bio and disclosures
1/4 Next Chapter
 
A closer look at the role of eosinophils

The panel considers the pathogenic mechanisms leading to eosinophilic airway inflammation, how to dissect them by measuring specific biomarkers and how inhibiting these mechanisms with biologics might affect patient outcomes.

view bio and disclosures
2/4 Next Chapter
 
Challenges in the diagnosis of respiratory inflammatory diseases

The panel discusses how biomarkers are used in the clinic to define disease phenotype and how they can inform on the optimal therapeutic approach for inflammatory respiratory diseases.

view bio and disclosures
3/4 Next Chapter
 
The future of anti-eosinophil therapy in the management of respiratory disease

The panel considers the impact of biologics in clinical practice for their patients with inflammatory respiratory diseases and how new indications for existing biologics and emerging agents may address remaining unmet treatment needs.

view bio and disclosures
4/4 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

In this activity, a panel of experts discuss how to identify and manage patients with eosinophilic inflammatory diseases of the respiratory system, with a focus on severe eosinophilic asthma and the use of biological therapies targeting the type 2 inflammatory pathway.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognize the role of eosinophils and type 2 inflammation in respiratory disease
  • Understand the diagnostic methods used to differentiate inflammatory diseases of the respiratory system
  • Recall disease states that may benefit from therapies that target the complex interaction between eosinophils and their environment
Faculty & Disclosures
Dr Harissios Vliagoftis

University of Alberta, Edmonton, Alberta, Canada

Harissios Vliagoftis, MD, PhD, is currently Professor at the Division of Pulmonary Medicine, Department of Medicine, University of Alberta and a practicing allergist at the University of Alberta Hospital. He is a clinician scientist and holds the GSK/CIHR (Canadian Institutes of Health Research) Chair in Airway Inflammation. read more

Dr Vliagoftis has published over 75 peer-reviewed publications, mainly in the area of allergic airway inflammation, which has been the main research interest of his laboratory. His laboratory is currently funded by the CIHR, the Women and Children’s Health Research Institute and the GSK/CIHR Chair in Airway Inflammation.

Dr Vliagoftis is a member of the Board of the Canadian Society of Allergy and Clinical Immunology and of the Advanced Education and Training Opportunities Advisory Committee of AllerGEN NCE. He is an Associate Editor for Allergy Asthma and Clinical Immunology, and is on the Editorial Board of Clinical and Experimental Allergy.

Dr Vliagoftis discloses: Advisory board fees from AstraZeneca and CSL Behring. Educational grants from Pfizer Canada. Funds for investigator-initiated studies from CSL Behring. Speaker’s honoraria from Aralez, AstraZeneca, GlaxoSmithKline, Medexus Pharma Canada and Novartis.

Prof. Ian Pavord

University of Oxford and Oxford University Hospitals, Oxford, UK

Ian D Pavord, MA, DM, FRCP, FERS, FMedSci is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He was elected a National Institute for Health Research Senior Investigator in 2011 and 2014, an inaugural Fellow of the European Respiratory Society (ERS) in 2014 and a Fellow of the Academy of Medical Science in 2015. read more

His research interests are in the clinical aspects of inflammatory airway diseases and he has pioneered the use of non-invasive measures of airway inflammation in the assessment of these conditions. He has identified several clinically important phenotypes and biomarkers of inflammatory airway disease, and has played a lead role in the clinical development of three of the most promising new treatments for severe airway disease.

Prof. Pavord is the author of over 480 publications and has an H-index of 111, making him the 2nd highest cited researcher in asthma, worldwide. He was Chief Medical Officer of Asthma UK from 2008–2014, co-editor of Thorax from 2010–2015, Associate Editor of the American Journal of Respiratory and Critical Care Medicine from 2005–2010 and has been Associate Editor of the European Respiratory Journal since 2016. He received the 2016 ERS Gold Medal for his research and gave the Cournand Lecture at the 2004 ERS meeting.

Prof. Pavord discloses: Advisory panel fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Merck, Novartis, Sanofi/Regeneron and Teva. Clinical trial grants from Chiesi. Co-patent holder of the Leicester Cough Questionnaire. Educational event organization fees from AstraZeneca, GSK, Sanofi/Regeneron and Teva. Expert witness for a patent dispute in 2014–2015 involving AstraZeneca and Teva. FDA approval meetings support fees from GlaxoSmithKline. Fees for use of the Leicester Cough Questionnaire from Bayer, Insmed and Merck. Speaker’s honoraria from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi/Regeneron and Teva. Sponsorship for international scientific meeting attendance from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Teva.

Prof. Alberto Papi

University of Ferrara, Ferrara, Italy

Alberto Papi is Professor and Chair of Respiratory Medicine at the School of Medicine of the University of Ferrara and Head of the Respiratory Unit of the Emergency Department, St. Anna University Hospital, Ferrara, Italy. He is Director of the Research Center on Asthma and COPD (CEMICEF) at the Department of Translational Medicine, University of Ferrara. read more

Prof. Papi trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer. Prof. Papi’s main area of research is airway inflammation in asthma and chronic obstructive pulmonary disease (COPD), its molecular mechanisms and pharmacological modulation. In particular, he has an interest in the role of respiratory viral infections in stable/exacerbated obstructive lung diseases, and the underlying molecular and immunological mechanisms.

Prof. Papi has served as Member of the Asthma Board of the European Academy of Allergy and Clinical Immunology, and as Secretary of the Respiratory Infections Group of the European Respiratory Society. He is also a member of the Editorial Board of the American Journal of Respiratory and Critical Care Medicine and the Journal of COPD. He has coordinated several pivotal studies in asthma and COPD, and has authored more than 400 articles in peer-reviewed journals.

Prof. Papi discloses: Advisory board, board member or consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Edmondpharma, Farmaceutici, GlaxoSmithKline, Mundipharma, Novartis, Sanofi/Regeneron, Teva and Zambon. Industry-sponsored grants from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Fondazione Chiesi, Fondazione Maugeri, GlaxoSmithKline and Menarini. Lecture fees from AstraZeneca, Chiesi Farmaceutici, Boehringer Ingelheim, Gentili, GlaxoSmithKline, Mundipharma, Novartis, Pfizer, Teva and Zambon. Member of The GOLD Science Committee.

Downloads

View and download resources from this activity to support your learning or share with colleagues

Register to touchRESPIRATORY for FREE
  • Peer-reviewed journals and expert opinions.
  • Interactive CME and e-learning modules.
  • Video conference highlights.
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchPANEL DISCUSSION on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72